Literature DB >> 7378389

Synthesis and characterization of phosphocitric acid, a potent inhibitor of hydroxylapatite crystal growth.

W P Tew, C Mahle, J Benavides, J E Howard, A L Lehninger.   

Abstract

Human urine and extracts of rat liver mitochondria contain apparently identical agents capable of inhibiting the precipitation or crystallization of calcium phosphate. Its general properties, as well as 1H NMR and mass spectra, have suggested that the agent is phosphocitric acid. This paper reports the synthesis of phosphocitric acid via the phosphorylation of triethyl citrate with o-phenylene phosphochloridate, hydrogenolysis of the product to yield triethyl phosphocitrate, hydrolytic removal of the blocking ethyl groups and also chromatographic purification. An enzymatic assay of phosphocitrate is described. Synthetic phosphocitrate was found to be an exceedingly potent inhibitor of the growth of hydroxylapatite seed crystals in a medium supersaturated with respect to Ca2+ and phosphate. Comparative assays showed phosphocitrate to be much more potent than the most active precipitation-crystallization inhibitors previously reported, which include pyrophosphate and ATP. 14C-Labeled phosphocitrate was bound very tightly to hydroxylapatite crystals. Such binding appeared to be essential for its inhibitory activity on crystal growth. Citrate added before but not after, phosphocitrate greatly enhanced the inhibitory potency of the latter. This enhancement effect was not given by other tricarboxylic acids. The monoethyl ester of phosphocitrate had no inhibitory effect on hydroxylapatite crystal growth.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378389     DOI: 10.1021/bi00550a039

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Structural factors influencing the ability of compounds to inhibit hydroxyapatite formation.

Authors:  G Williams; J D Sallis
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

Review 2.  Phosphocitrate as a potential therapeutic strategy for crystal deposition disease.

Authors:  H S Cheung
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.592

3.  Glycochenodeoxycholic acid inhibits calcium phosphate precipitation in vitro by preventing the transformation of amorphous calcium phosphate to calcium hydroxyapatite.

Authors:  S M Qiu; G Wen; N Hirakawa; R D Soloway; N K Hong; R S Crowther
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

4.  Adsorption and mineralization effects of citrate and phosphocitrate on hydroxyapatite.

Authors:  M Johnsson; C F Richardson; J D Sallis; G H Nancollas
Journal:  Calcif Tissue Int       Date:  1991-08       Impact factor: 4.333

5.  Phosphocitrate inhibits mitochondrial and cytosolic accumulation of calcium in kidney cells in vivo.

Authors:  W P Tew; C D Malis; J E Howard; A L Lehninger
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

6.  Phosphocitrate is potentially a disease-modifying drug for noncrystal-associated osteoarthritis.

Authors:  Yubo Sun; David R Mauerhan; Atiya M Franklin; James Norton; Edward N Hanley; Helen E Gruber
Journal:  Biomed Res Int       Date:  2013-02-21       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.